The Verdict
Scott Minerd has returned +24.5% vs S&P +6.2% over matched windows (61% win rate across 19 picks).
The Report Card
Every pick at a glance. Green = beat S&P. Red = didn't.
Scott Minerd's Stock Recommendations, Graded
- DNTH · BUY · Mar 15, 2026
Dianthus Therapeutics
Return +11.7% vs S&P +6.9%
- S · BUY · Mar 14, 2026
SentinelOne
Return +2.4% vs S&P +6.9%
- GRAL · BUY · Mar 14, 2026
GRAIL Inc
Return +20.3% vs S&P +6.9%
- FWONK · BUY · Mar 13, 2026
Liberty Formula One
Return +3.6% vs S&P +8.0%
Scott Minerd's Best and Worst Stock Picks
Best: RLAY (+268.2%) · Worst: MNDY (-56.0%).
Scott Minerd's Full Track Record
| Action | Ticker | Date | Headline | Return | vs S&P |
|---|
| BUY | DNTH | | DNTH: Dianthus Therapeutics — BUY Mar 2026Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) | +11.7% | +4.8% |
| BUY | S | | S: SentinelOne — BUY Mar 2026Guggenheim Reaffirms Their Buy Rating on SentinelOne (S) | +2.4% | -4.5% |
| BUY | GRAL | | GRAL: GRAIL Inc — BUY Mar 2026Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL) | +20.3% | +13.4% |
| BUY | FWONK | | FWONK: Liberty Formula One — BUY Mar 2026Guggenheim reiterates Liberty Formula One stock Buy on race cancellations | +3.6% | -4.3% |
| BUY | ORKA | | ORKA: Oruka Therapeutics — BUY Mar 2026Oruka Therapeutics (NASDAQ:ORKA) Earns "Buy" Rating from Guggenheim | +91.0% | +83.0% |
| BUY | SGMT | | SGMT: Sagimet Biosciences — BUY Mar 2026Guggenheim Maintains Sagimet Biosciences(SGMT.US) With Buy Rating | +55.9% | +47.9% |
| BUY | RLAY | | RLAY: Relay Therapeutics — BUY Mar 2026Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price | +44.3% | +36.3% |
| BUY | ABBV | | ABBV: AbbVie — BUY Mar 2026Guggenheim Reiterates Buy Rating on Abbvie (ABBV) | -12.4% | -19.8% |
| BUY | VYGR | | VYGR: Voyager Therapeutics — BUY Mar 2026Guggenheim Remains a Buy on Voyager Therapeutics (VYGR) | -22.8% | -30.2% |
| BUY | ONC | | ONC: BeOne Medicines — BUY Feb 2026Guggenheim Forecasts Strong Price Appreciation for BeOne Medicines | -5.7% | -10.0% |
| BUY | RYTM | | RYTM: Rhythm Pharmaceuticals — BUY Feb 2026Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals | -8.1% | -12.4% |
| BUY | LOW | | LOW: Lowe's Companies — BUY Feb 2026Guggenheim Forecasts Strong Price Appreciation for Lowe's Companies | -8.3% | -12.0% |
| BUY | ATAI | | ATAI: AtaiBeckley — BUY Jan 2026Guggenheim Initiates Buy Rating for AtaiBeckley | +15.4% | +12.1% |
| BUY | ORCL | | ORCL: Oracle Corporation — BUY Dec 2025Oracle stock remains Guggenheim's Best Idea | -13.0% | -16.8% |
| BUY | MNDY | | MNDY: Monday.com — BUY Dec 2025Monday.com stock initiated with Buy rating at Guggenheim | -56.0% | -60.5% |
| BUY | CYBN | | CYBN: Cybin Inc. — BUY Dec 2025Guggenheim raises Cybin stock price target | +37.8% | +37.0% |
| SELL | GTLB | | GTLB: GitLab — SELL Sep 2025Guggenheim Asserts GitLab's Inc. 'Buy' Rating | ✓ Correct | +65.7% |
| BUY | SMMT | | SMMT: Summit Therapeutics — BUY Sep 2025Guggenheim Initiates Summit Therapeutics With a Buy Rating | +17.5% | +7.5% |
| BUY | RLAY | | RLAY: Relay Therapeutics — BUY Sep 2025Guggenheim Gives Buy Rating to Relay Therapeutics | +268.2% | +258.0% |
FAQ
Is Scott Minerd good at picking stocks?
Scott Minerd has 19 scored picks with 61% win rate and +18.3% vs S&P.
What stocks does Scott Minerd recommend?
RLAY, SMMT, GTLB, CYBN, MNDY, ORCL.
What date range does this track record cover?
Sep 07, 2025 to Mar 15, 2026.
Share Card
